Healthcare / Medical DevicesTokyo
$1420.00
-27.00 (-1.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $710.8M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.9B
P/E
9.6x
↓EV/EBITDA
5.7x
↓ROE
25.7%
↑Gross Margin
67.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.0%
FCF CAGR
+111.2%
FCF margin
10.3%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.92B · net income $1.33B · FCF $710.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.92B | $6.92B | $5.94B | $5.41B | $4.66B |
| Net Income | $1.33B | $1.33B | $1.02B | $645.0M | $610.5M |
| EBITDA | $1.88B | $1.88B | $1.58B | $1.10B | $1.02B |
| EPS | 145.54 | 145.54 | 112.28 | 70.63 | 66.84 |
| Gross Margin | 67.3% | 67.3% | 66.8% | 63.9% | 65.3% |
| Operating Margin | 26.2% | 26.2% | 25.2% | 18.8% | 20.4% |
| Net Margin | 19.2% | 19.2% | 17.2% | 11.9% | 13.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 |
| Current Ratio | 3.09 | 3.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $710.8M | $710.8M | $357.3M | $867.3M | $75.5M |
| Returns | |||||
| ROE | 25.7% | 25.7% | 24.9% | 19.7% | 22.2% |
| Valuation | |||||
| P/E | 9.57 | 9.57 | 9.08 | 12.94 | 12.57 |
| EV/EBITDA | 5.74 | 5.74 | 4.76 | 5.94 | 6.45 |
| P/B | 2.51 | 2.51 | 2.26 | 2.56 | 2.79 |
| Growth & Yield | |||||
| Revenue Growth | 16.4% | 16.4% | 10.0% | 15.9% | — |
| EPS Growth | 29.6% | 29.6% | 59.0% | 5.7% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.7%
EPS terminal req.
$126.00
Spread vs growth
34.3%
5Y implied EPS CAGR
0.9%
EPS terminal req.
$152.46
Spread vs growth
28.7%
10Y implied EPS CAGR
5.4%
EPS terminal req.
$245.54
Spread vs growth
24.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.0%
Start / end P/E
11.9x → 9.8x
EPS bridge
112.28 → 145.54
Residual
-5.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.